DrugPatentWatch Database Preview

Janssen R And D Company Profile

JANSSEN R AND D has two approved drugs.

There are four US patents protecting JANSSEN R AND D drugs.

There are one hundred and thirty-four patent family members on JANSSEN R AND D drugs in thirty-nine countries and twelve supplementary protection certificates in eleven countries.

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008		RX	Yes	No	7,037,917*PED	➤ Sign Up			Y	➤ Sign Up
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-003	Mar 26, 2012		RX	Yes	No		➤ Sign Up				➤ Sign Up
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008		RX	Yes	No		➤ Sign Up				➤ Sign Up
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-002	Dec 22, 2010		RX	Yes	Yes	7,037,917*PED	➤ Sign Up			Y	➤ Sign Up
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-002	Dec 22, 2010		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	005423	➤ Sign Up
Poland	348145	➤ Sign Up
Hungary	0203568	➤ Sign Up
Croatia	P20010310	➤ Sign Up
Taiwan	541305	➤ Sign Up
Country	Patent Number	Estimated Expiration

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1002795	SPC/GB09/003	United Kingdom	➤ Sign Up	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
1002795	SPC033/2008	Ireland	➤ Sign Up	SPC033/2008: 20090914, EXPIRES: 20230827
1002795	122009000003	Germany	➤ Sign Up	PRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
1002795	09C0004	France	➤ Sign Up	PRODUCT NAME: ETRAVIRINE AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/468/001 DU 20080828; REGISTRATION NO/DATE AT EEC: EU/1/08/468/001 DU 20080828
1002795	337	Finland	➤ Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.